Skip to main content
RUA LIFE SCIENCES PLC logo

RUA LIFE SCIENCES PLC — Investor Relations & Filings

Ticker · RUA ISIN · GB0033360586 LEI · 213800BMVB22PVOJ9Z28 IL Manufacturing
Open in API
Filings indexed 200 across all filing types
Latest filing 2020-03-30 M&A Activity
Country GB United Kingdom
Listing IL RUA

About RUA LIFE SCIENCES PLC

https://rualifesciences.com/

RUA Life Sciences is a medical device group focused on the application of its proprietary long-term implantable polymer, Elast-Eon™, a biostable polyurethane. The company operates through four integrated businesses to develop, manufacture, and license medical device solutions. RUA Biomaterials is responsible for licensing the Elast-Eon™ technology. RUA Medical provides end-to-end contract development and manufacturing services, specializing in implantable fabrics. RUA Vascular develops large-bore, polymer-sealed vascular grafts and soft tissue patches. RUA Structural Heart is engaged in the development of next-generation tri-leaflet polymeric heart valves. The group's collective mission is to improve patient outcomes by enabling and enhancing medical devices through its advanced polymer technology.

Recent filings

Filing Released Lang Actions
Update re Acquisition of RUA and COVID-19
M&A Activity Classification · 1% confidence The document begins with 'RNS Number : 0997I' and concludes with information about RNS, the news service of the London Stock Exchange, stating it is an 'approved Primary Information Provider'. The content discusses an update regarding a proposed acquisition (RUA Medical Devices Limited) and the impact of COVID-19, including changes to consideration payment terms. This type of immediate, material, non-periodic corporate disclosure, especially when flagged with an RNS number, strongly indicates a general regulatory announcement. Since the content is not a full financial report (10-K, IR), a specific management change (MANG), or a director's dealing (DIRS), the most appropriate classification is the general regulatory filing category, RNS.
2020-03-30 English
Update re Acquisition and General Meeting
Regulatory Filings Classification · 1% confidence The document is an RNS announcement (RNS Number : 4584H) dated March 25, 2020, concerning an update regarding a proposed acquisition (RUA Medical Devices Limited) and the logistics of an upcoming General Meeting scheduled for March 31, 2020. It discusses potential adjournment due to COVID-19 and strongly encourages shareholders to submit proxy forms by a specific deadline (March 27, 2020). Since the document is an official regulatory announcement from the London Stock Exchange's news service (RNS) detailing procedural updates related to a shareholder vote (General Meeting), it fits best under the general Regulatory Filings category (RNS) or potentially AGM-R if the focus was purely on the AGM materials. However, because it is an update/announcement published via RNS regarding meeting logistics and proxy voting instructions, RNS is the most appropriate general classification for this type of market communication, although AGM-R is also relevant due to the General Meeting context. Given the structure and source (RNS Number), RNS is chosen as the primary classification for this regulatory update.
2020-03-25 English
Proposed Acquisition of RUA Medical & Name Change
Regulatory Filings Classification · 1% confidence The document is an announcement dated March 11, 2020, identified by the RNS Number (Regulatory News Service), which is characteristic of regulatory disclosures in the UK market. The content details a 'Proposed Acquisition' and a 'Change of Name,' which are significant corporate actions requiring immediate public disclosure. The text explicitly mentions that it 'contains inside information and is disclosed in accordance with the Company's obligations under the Market Abuse Regulation (EU) No 596/2014.' This strongly indicates a formal regulatory announcement. Since the document is a detailed announcement about a major transaction (M&A) and a name change, it is not a general 'Report Publication Announcement' (RPA) or a generic 'Regulatory Filing' (RNS) fallback, but rather a specific corporate action disclosure. However, none of the specific codes (like TAR for M&A) perfectly capture the nature of a comprehensive announcement covering acquisition, name change, and director changes simultaneously, especially when it is disseminated via RNS. Given the options, the closest fit for a major corporate action announcement disseminated via the regulatory news service (RNS) that doesn't fit perfectly into ER, 10-K, or IR is often categorized under the general regulatory announcement umbrella. Since the core event is a takeover/acquisition proposal, TAR (M&A Activity) is a strong candidate, but the document is primarily an RNS announcement detailing the transaction terms and subsequent name change. Because it is a formal regulatory news service release detailing a significant corporate event (acquisition and name change), and RNS is the mechanism used, I will check if TAR is better than RNS. Since the primary focus is the acquisition, TAR is more specific than RNS. However, the document structure is that of a standard RNS release. Let's re-evaluate the definitions. TAR is for 'Merger proposals or takeover bids.' This document is an announcement of entering into a conditional agreement for an acquisition. This fits TAR well. The document is substantial (over 33k characters) and contains the full details, not just a notice that a report is attached (ruling out RPA/RNS based on the 'Menu vs Meal' rule if it were a report announcement). Therefore, M&A Activity (TAR) is the most appropriate specific classification for the primary subject matter (Proposed Acquisition).
2020-03-11 English
Extension to Agreement with RUA Medical
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and is dated January 21, 2020. It announces an 'Extension to Agreement with RUA Medical' and provides details about the business partnership and future commercial strategy. The presence of the RNS Number and the nature of the announcement (a material business update/extension of a commercial agreement) strongly suggest this is a regulatory disclosure disseminated via the London Stock Exchange's news service. Since it is a general business announcement that doesn't fit specific categories like M&A (TAR), Capital Change (CAP), or Director Dealing (DIRS), the most appropriate classification is the general regulatory filing category, RNS.
2020-01-21 English
Heart Valve Development Update
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and is dated '06 January 2020'. It provides an update on the company's heart valve development, including commitment to bespoke equipment and securing grant aid. The closing section explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This structure and explicit attribution strongly indicate a general regulatory announcement disseminated via the London Stock Exchange's Regulatory News Service (RNS). Since the content is an operational update rather than a formal financial report (like 10-K or IR) or a specific corporate action announcement (like DIV or CAP), the most appropriate classification is the general regulatory filing category.
2020-01-06 English
New Share Option Scheme and Grant of Share Options
Regulatory Filings Classification · 1% confidence The document is identified by the 'RNS Number' header and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' The content details the adoption of a new share option scheme and the grant of options to Non-Executive Directors. This type of announcement, concerning insider transactions (share options granted to directors) and corporate governance actions, is typically disseminated via regulatory news services. While it relates to director dealings (DIRS) or capital changes (SHA), the primary context is a general regulatory announcement disseminated through RNS, and it is not a full financial report or a specific proxy statement. Given the explicit RNS identification and the nature of the announcement (granting options to directors), it fits best under the general regulatory filing category (RNS) or potentially Director's Dealing (DIRS). Since it is an announcement of an internal corporate action disseminated via the RNS system, RNS is the most appropriate general classification, although DIRS is also highly relevant. Given the structure, RNS serves as the appropriate catch-all for these types of market updates originating from the LSE's news service.
2019-12-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.